Winslow Capital Management LLC Sells 2,647,680 Shares of Boston Scientific Corporation $BSX

Key Points

• Winslow Capital Management cut its stake in Boston Scientific by 99.6% in Q2, selling 2,647,680 shares and retaining 10,660 shares worth about $1.145 million.
• Insider selling accelerated: company insiders sold 143,095 shares (~$14.23 million) in the past three months, including EVP Joseph M. Fitzgerald (50,000 shares) and Director Ellen M. Zane (12,891 shares).
• Analyst sentiment remains positive with a consensus "Buy" and an average target of $123.77, while Boston Scientific guided FY2025 EPS of $3.020–3.040 and several firms recently raised price targets.

Winslow Capital Management LLC trimmed its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 99.6% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,660 shares of the medical equipment provider's stock after selling 2,647,680 shares during the quarter. Winslow Capital Management LLC's holdings in Boston Scientific were worth $1,145,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider's stock valued at $14,729,575,000 after acquiring an additional 2,545,381 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Boston Scientific by 2.0% during the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider's stock worth $3,466,320,000 after purchasing an additional 622,602 shares in the last quarter. Norges Bank purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at $2,089,937,000. Invesco Ltd. lifted its holdings in shares of Boston Scientific by 1.4% during the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider's stock valued at $1,810,022,000 after purchasing an additional 226,578 shares during the last quarter. Finally, Amundi boosted its position in shares of Boston Scientific by 2.6% in the 1st quarter. Amundi now owns 12,308,715 shares of the medical equipment provider's stock worth $1,212,408,000 after purchasing an additional 311,034 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on BSX shares. Evercore ISI reaffirmed an "outperform" rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Wells Fargo & Company increased their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the company an "overweight" rating in a research report on Thursday, October 23rd. Truist Financial lifted their target price on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a "buy" rating in a research note on Thursday, October 23rd. Weiss Ratings restated a "buy (b-)" rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Finally, Barclays raised their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an "overweight" rating in a report on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $123.77.

Insiders Place Their Bets

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Ellen M. Zane sold 12,891 shares of the business's stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares of the company's stock, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 143,095 shares of company stock valued at $14,228,950. Company insiders own 0.50% of the company's stock.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $97.46 on Monday. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The company has a market cap of $144.48 billion, a PE ratio of 52.12, a price-to-earnings-growth ratio of 1.96 and a beta of 0.67. The company's 50 day moving average is $99.27 and its 200 day moving average is $102.02.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the prior year, the firm earned $0.63 EPS. The business's revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.